ZA200905962B - Combination therapy for treatment of immune disorders - Google Patents

Combination therapy for treatment of immune disorders

Info

Publication number
ZA200905962B
ZA200905962B ZA200905962A ZA200905962A ZA200905962B ZA 200905962 B ZA200905962 B ZA 200905962B ZA 200905962 A ZA200905962 A ZA 200905962A ZA 200905962 A ZA200905962 A ZA 200905962A ZA 200905962 B ZA200905962 B ZA 200905962B
Authority
ZA
South Africa
Prior art keywords
treatment
combination therapy
immune disorders
immune
disorders
Prior art date
Application number
ZA200905962A
Other languages
English (en)
Inventor
Edward Paul Bowman
Daniel J Cua
Robert A Kastelein
Kathy Lynn Miller
Melanie A Kleinschek
Kristian Sass Bak-Jensen
Katia Boniface
Brent S Mckenzie
Waal Malefyt Rene De
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200905962B publication Critical patent/ZA200905962B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
ZA200905962A 2007-02-28 2009-08-27 Combination therapy for treatment of immune disorders ZA200905962B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89214207P 2007-02-28 2007-02-28
US94527907P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
ZA200905962B true ZA200905962B (en) 2010-05-26

Family

ID=39596554

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905962A ZA200905962B (en) 2007-02-28 2009-08-27 Combination therapy for treatment of immune disorders

Country Status (11)

Country Link
US (3) US20100135998A1 (fr)
EP (3) EP2417974A1 (fr)
JP (2) JP5337055B2 (fr)
CN (2) CN103933573A (fr)
AU (1) AU2008219681A1 (fr)
BR (1) BRPI0807987A2 (fr)
CA (1) CA2679400A1 (fr)
MX (1) MX2009009167A (fr)
NZ (2) NZ579297A (fr)
WO (1) WO2008106131A2 (fr)
ZA (1) ZA200905962B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (fr) 2006-06-13 2007-12-21 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procedes d'utilisation
EP2215123A1 (fr) 2007-11-27 2010-08-11 Ablynx N.V. Constructions d'immunoglobuline
WO2010054185A1 (fr) * 2008-11-06 2010-05-14 Ambit Biosciences Corporation Dosage de biomarqueur de la tyrosine kinase 3 apparentée à fms phosphorylée
EP3683317A3 (fr) 2009-05-13 2020-09-30 Genzyme Corporation Immunoglobulines anti-cd52 humain
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
BR112012019881A2 (pt) 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
US8858944B2 (en) 2010-06-02 2014-10-14 Sumitomo Dainippon Pharma Co., Ltd. Treatment drug for autoimmune diseases and allergic diseases
WO2012032181A2 (fr) 2010-09-10 2012-03-15 Allozyne, Inc Nouveaux dérivés d'anticorps
GEP201706733B (en) 2010-11-04 2017-09-25 Boehringer Ingelheim Int Anti-il-23 antibodies
CA2840270C (fr) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methodes de traitement de troubles chroniques au moyen d'inhibiteurs de complement
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
EP3326649B1 (fr) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anticorps anti-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2014180577A1 (fr) * 2013-05-10 2014-11-13 Numab Ag Constructions bispécifiques et leur utilisation dans le traitement de plusieurs maladies
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
EP3172339A1 (fr) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarqueurs utiles dans le traitement de maladies associées à l'il-23a
BR112017004169A2 (pt) * 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CN108135983A (zh) * 2015-10-30 2018-06-08 伊莱利利公司 抗cgrp /抗il-23双特异性抗体及其用途
EA201892190A1 (ru) * 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
CN108113999A (zh) * 2016-11-29 2018-06-05 浦项工科大学校产学协力团 以Th17细胞为有效成分包含的代谢性疾病预防或治疗用细胞治疗剂组合物
CA3045475A1 (fr) * 2016-12-14 2018-06-21 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur des interleukines il-12/il-23 libere a l'aide d'un dispositif ingerable
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体
US20210093669A1 (en) * 2019-09-26 2021-04-01 Nantbio, Inc. Primary T-Cell Expansion
WO2021146850A1 (fr) * 2020-01-20 2021-07-29 Tsinghua University Rôle critique de la température febrile dans la régulation de cellules produisant de l'interleukine-17 par smad4

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6319522B1 (en) * 1990-07-13 2001-11-20 Gropep Limited Growth-promoting agent
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE69334305D1 (de) 1992-08-21 2010-01-28 Univ Bruxelles Immunoglobuline ohne leichte Ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
AU7324094A (en) * 1993-07-16 1995-02-13 Schering Corporation Cell surface protein present on nk (natural killer cells) named dx1
WO1995020604A1 (fr) 1994-01-28 1995-08-03 Schering Corporation Anticorps specifiques des antigenes de cellules tueuses naturelles des mammiferes et utilisations correspondantes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE279517T1 (de) 1995-03-23 2004-10-15 Immunex Corp Il-17 receptor
WO1997003715A1 (fr) 1995-07-21 1997-02-06 The General Hospital Corporation Procede et appareil permettant de faciliter l'administration d'une preparation pharmaceutique
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
WO2000053631A1 (fr) 1999-03-11 2000-09-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes
MXPA02002684A (es) 1999-09-09 2002-07-30 Schering Corp Citocinas de mamifero; reactivos y metodos relacionados.
WO2001023556A1 (fr) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7169580B1 (en) * 2000-02-03 2007-01-30 Chugai Seiyaku Kabushiki Kaisha Protein having PGE2 synthase activity and use thereof
AU2001261351B2 (en) * 2000-05-10 2007-03-01 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
AU2002223182B2 (en) 2000-10-06 2007-08-30 Immunex Corporation Hematopoietin receptors HPR1 and HPR2
AU2002225714A1 (en) 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20050261219A1 (en) 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
EP1487879B1 (fr) * 2002-03-01 2012-12-26 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
WO2003086310A2 (fr) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention de l'inflammation du cerveau en tant que resultat d'une reponse auto-immune induite
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004071517A2 (fr) 2003-02-06 2004-08-26 Schering Corporation Utilisations de cytokine de mammifere; reactifs associes
CL2004000467A1 (es) 2003-03-10 2005-05-06 Schering Corp Uso de un anticuerpo contra la subunidad p19 de interleuquina 23 (il-23), para preparar una composicion para el tratamiento de cnacer o de tumores. ]
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7130995B2 (en) 2003-09-30 2006-10-31 International Business Machines Corporation Secure switching for downloading network boots
US20060193821A1 (en) 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2005087810A2 (fr) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Proteines de fusion dimeres et materiaux et methodes de production de ces proteines
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7851466B2 (en) 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
ES2410406T3 (es) * 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
JP5350793B2 (ja) 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション 改変抗ｉｌ−２３抗体
CA2621086A1 (fr) * 2005-09-01 2007-03-08 Schering Corporation Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
BRPI0620946B8 (pt) 2005-12-29 2021-05-25 Centocor Inc anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
CA2655372A1 (fr) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procedes d'utilisation
CA2652924A1 (fr) * 2006-06-19 2007-12-27 Wyeth Procedes de modulation de l'il-22 et de l'il-17
US20080019970A1 (en) 2006-07-07 2008-01-24 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
KR101218484B1 (ko) 2006-08-11 2013-01-04 머크 샤프 앤드 돔 코포레이션 Ｉｌ-17ａ에 대한 항체
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto

Also Published As

Publication number Publication date
WO2008106131A2 (fr) 2008-09-04
AU2008219681A1 (en) 2008-09-04
JP2010520197A (ja) 2010-06-10
US20100135998A1 (en) 2010-06-03
WO2008106131A3 (fr) 2008-12-11
EP2425838A2 (fr) 2012-03-07
EP2425838A3 (fr) 2012-05-02
JP5337055B2 (ja) 2013-11-06
US20120156699A1 (en) 2012-06-21
EP2417974A1 (fr) 2012-02-15
BRPI0807987A2 (pt) 2014-06-24
JP2012251002A (ja) 2012-12-20
NZ597915A (en) 2013-08-30
EP2056838A2 (fr) 2009-05-13
CA2679400A1 (fr) 2008-09-04
MX2009009167A (es) 2009-09-04
NZ579297A (en) 2012-03-30
US20130287775A1 (en) 2013-10-31
CN101668531A (zh) 2010-03-10
CN103933573A (zh) 2014-07-23
CN101668531B (zh) 2014-05-07
EP2056838B1 (fr) 2013-09-25

Similar Documents

Publication Publication Date Title
ZA200905962B (en) Combination therapy for treatment of immune disorders
IL259475A (en) Combined therapy for the treatment of diabetes
EP2166837A4 (fr) Combinaison médicamenteuse utilisable pour le traitement de troubles cutanés
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL253293A0 (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
ZA201106730B (en) Methods of treatment using combination therapy
ZA201001262B (en) Interval therapy for the treatment of tinnitus
AU324215S (en) Handpiece for massage or therapy
PT2247297T (pt) Tratamento terapêutico para estados pulmonares
EP2185162A4 (fr) Thérapie polymère utilisée dans le traitement de maladies microvasculaires chroniques
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
EP2231181A4 (fr) Nouveau vaccin pour le traitement de troubles liés à une mycobactérie
GB0809476D0 (en) Treatment of neurodegenerative disorders
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
EP2328584A4 (fr) Traitement de troubles neurologiques à l'aide d'huperzine
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
HK1175096A1 (en) Therapeutic gas for the treatment of mitochondrial disorders
EP2203174A4 (fr) Régimes thérapeutiques pour le traitement de troubles immunoinflammatoires
EP2212246B1 (fr) Traitement de troubles neurologiques
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
GB0814043D0 (en) The treatment of skin disorders
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
HK1145282A1 (en) Treatment of sleep disorders
GB0711403D0 (en) Therapy for immune disorders